Innovative Pipeline Oxurion's focus on developing next-generation ophthalmic therapies such as THR-149 and THR-687 presents opportunities to expand into specialized ophthalmology markets, especially targeting retinal disorder treatments where existing options have room for enhancement.

Strategic Funding The company has secured multiple rounds of significant funding, including over EUR 3.5 million, enabling further clinical development and potential partnership discussions with investors, BIOs, and healthcare providers interested in cutting-edge retinal therapies.

Market Focus With a core emphasis on diabetic macular oedema, particularly subgroups unresponsive to standard anti-VEGF treatments, there is potential to collaborate with clinics and healthcare systems exploring alternative or complementary therapies for retinal disorders.

Geographic Expansion Headquartered in Belgium with operations in Boston, Oxurion is positioned to leverage European and North American markets, making it an attractive partner for regional distribution, clinical trials, and market access collaborations.

Technological Edge Utilization of advanced web technologies and a strong digital presence indicates readiness for engaging with academic, clinical, and industry partners through targeted outreach and digital marketing strategies to foster partnerships and sales channels.